Comparison of the effectiveness and safety between lymphocytes scavenger and IL-2 receptor blocking agent induction in living kidney transplantation
- Author:
Ning-bo QIN
1
Author Information
1. Hebei North University
- Publication Type:Journal Article
- Keywords:
Antithymocyte globulin;
Interleukin-2;
Kidney transplantation;
Receptors
- From:
Medical Journal of Chinese People's Liberation Army
2013;38(3):235-239
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the safety of two antibody inductors, namely lymphocytes scavenger and IL-2 receptor blocking agent, in living kidney transplantation. Methods The data of 191 patients, who received living kidney transplant in our hospital from Feb. 2007 to Jul. 2012, were retrospectively analyzed, and grouped according to the inductors they received as: a) lymphocytes scavenger group (n=56), with rabbit antithymocyte immunoglobulin (rATG, 4 cases) and porcine antihuman T-lymphocyte immunoglobulin (pATG, 52 cases) served as the inductor; b) IL-2 receptor blocking agent group (n=54), with basiliximab (40 cases) and daclizumab (14 cases) served as the inductor; and c) control group (n=8l). The incidence of rejection and infection, and the survival rate of patient/allograft within one year were then compared among the three groups. Results Within one year after the transplantation, the incidence of acute rejection in lymphocytes scavenger group, IL-2 receptor blocking agent group and control group was 12.5%, 11.1% and 28.4%, respectively. There was a significant difference between the two inductor groups and control group (P=0.003), but no significant difference was found between the two inductor groups (P>0.05). The incidence of delayed graft function (DGF) in the three groups was 8.9%, 7.4% and 13.6%, respectively, with no statistical significance (P>0.05). Also there was no significant difference among the three groups in the incidence of infection and the survival rate of patient/allograft within one year after transplantation (P>0.05). Conclusion Both inductors may significantly reduce the incidence of acute rejection within one year without increasing the incidence of infection and other adverse events, nor affect the postoperative patient/graft survival, so they are both safe and effective.
